8-K: Tharimmune Appoints COO, Names CEO Chairman

Tharimmune, Inc. announced the appointment of Angela Radkowski as Chief Operating Officer and the election of CEO Mark Wendland as Chairman of the Board, alongside regaining Nasdaq compliance.

Summary

• Angela Dominy Radkowski has been appointed Chief Operating Officer of Tharimmune, Inc., effective February 5, 2026.
• Mark Wendland, the current Chief Executive Officer, was elected Chairman of the Board, succeeding Vincent LoPriore, who will remain a Board member.
• The Board also elected new directors to serve on its Audit, Compensation, and Nominating & Corporate Governance Committees.
• Tharimmune regained compliance with Nasdaq Listing Rule 5605(b)(1) (Board Independence Rule) on February 2, 2026, following the election of two independent directors on January 30, 2026.
• Ms. Radkowski's employment agreement includes an annual base salary of $300,000, eligibility for a target annual cash bonus of $100,000 (prorated for 2026), and potential equity awards.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, reflecting strengthened leadership, improved corporate governance, and a clear strategic direction in the digital asset space, which could enhance investor confidence.

Positives

• Appointment of Angela Radkowski as Chief Operating Officer brings significant experience in scaling complex financial systems from DRW Holdings LLC and Citadel LLC.
• Regained compliance with Nasdaq's Board Independence Rule, resolving a previously reported deficiency and ensuring continued listing.
• Election of CEO Mark Wendland as Chairman of the Board unifies leadership and potentially streamlines strategic execution for the company's digital asset strategy.
• The company's clear strategic focus on leveraging Canton Coin and the Canton Network to digitize financial markets and drive institutional blockchain adoption is reinforced by these leadership changes.

Risks

• Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from expectations, as detailed in the company's annual and quarterly reports.
• The COO employment agreement includes customary restrictive covenants (non-compete, non-solicitation, confidentiality) which, if breached, could lead to legal action and associated costs.

Future Outlook

The company intends to continue executing its Canton Network-aligned digital asset strategy, including driving value through Canton Coin acquisition, operating as a Super Validator, and investing in applications built on the Canton Network to accelerate institutional utility and adoption across capital markets. The new COO will oversee operational control functions and enterprise processes, including the implementation of the Canton Network quarterly research initiative and Super Validator activation.

Management Comments

• "I am honored to assume the role of Chairman as we continue executing on our Canton Network-aligned digital asset strategy to help modernize financial market infrastructure." Mark Wendland, CEO and Chairman.
• "The Board, under the dedicated leadership of Vincent LoPriore, has demonstrated an unwavering commitment to building a governance and operating structure capable of supporting our digital asset treasury strategy, and Angelas appointment adds critical leadership at a pivotal moment." Mark Wendland.
• "Her experience scaling complex financial systems will be instrumental as we advance institutional adoption of Canton Network and drive value for shareholders." Mark Wendland.
• "The Canton Network introduces a new model for institutional finance – one that addresses the limitations of legacy infrastructure while enabling secure, scalable blockchain adoption." Angela Radkowski, COO.
• "I am excited to join Tharimmune and help build the operational foundation required to support this transformation." Angela Radkowski.

Industry Context

StockSavvy.ai notes that Tharimmune's dual focus on clinical-stage biotech research and digital asset treasury, specifically leveraging the Canton Network and Canton Coin, positions it uniquely in the market. The appointment of a COO with experience from major financial institutions like DRW Holdings and Citadel underscores a serious commitment to scaling its digital asset strategy, aligning with broader industry trends towards institutional adoption of blockchain technology in financial markets. This move suggests Tharimmune is actively building the operational infrastructure necessary to compete in the evolving digital finance landscape, while maintaining its biotech operations.

Comparison to Industry Standards

• Tharimmune positions itself as the "first publicly traded company to leverage Canton Coin" and the "first and only publicly traded company supported by the Canton Foundation," indicating a unique, early-mover strategy in this specific niche of digital asset treasury.
• The appointment of a COO with a background from DRW Holdings LLC and Citadel LLC suggests an attempt to bring high-caliber financial systems expertise, comparable to that found in established financial institutions, to its digital asset operations.
• The company's strategy to digitize traditional financial markets via the Canton Network aligns with broader industry efforts by major financial players (e.g., JPMorgan's Onyx, Goldman Sachs' digital asset initiatives) to explore blockchain for efficiency and new market opportunities, though Tharimmune's specific focus on Canton Coin provides a distinct approach.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strengthened leadership, improved corporate governance (Nasdaq compliance), and a clearer strategic direction in the digital asset space, potentially leading to increased shareholder value.
• Employees: The appointment of a new COO and the emphasis on operational foundation building may lead to organizational restructuring or new opportunities within the company, particularly in the digital asset division.
• Customers/Partners (Canton Network): The company's commitment to the Canton Network and its role as a Super Validator could enhance its standing and influence within the Canton ecosystem, potentially attracting more partners and users.

Next Steps

• Implementation of Tharimmune's Canton Network quarterly research initiative.
• Super Validator activation.
• Advancing institutional adoption of Canton Network.
• Driving value for shareholders through Canton Coin acquisition and Super Validator operations.
• Investing in applications built on the Canton Network.

Key Dates

Recommendation

The filing presents several positive developments, including strengthened leadership, improved corporate governance through Nasdaq compliance, and a clear strategic focus on digital assets. However, the company also operates in clinical-stage biotech, and the filing does not provide financial performance updates or specific details on the biotech segment. The digital asset strategy, while promising, is still in its early stages and subject to market volatility and regulatory uncertainties. A 'hold' recommendation is appropriate as investors should monitor the execution of the dual strategy and further financial disclosures across both business segments before making a more definitive investment decision.

Keywords

Tharimmune, THAR, Chief Operating Officer, COO, Chairman of the Board, Corporate Governance, Nasdaq Compliance, Canton Network, Canton Coin, Digital Assets, Blockchain, Financial Markets, Biotech, SEC Filing, 8-K